Researchers have developed an injectable hormone combination that can be taken by men to prevent pregnancy in their female partners.
While women can choose from a number of birth control methods, men have few options to control their own fertility. The available methods for men include condoms and withdrawal, which are less effective than hormonal birth control. Men can also have a vasectomy, but this method is invasive and often not reversible.
"The study found it is possible to have a hormonal contraceptive for men that reduces the risk of unplanned pregnancies in the partners of men who use it," said Mario Philip Reyes Festin from the World Health Organization (WHO) in Geneva, Switzerland.
The findings showed that a precise mixture of progestogen and testosterone lowered sperm count, can make men temporarily infertile.
For the study, the team tested the safety and effectiveness of injectable contraceptives in 320 healthy men aged between 18 to 45.
The men received injections of 200 milligrams of a long-acting progestogen called norethisterone enanthate (NET-EN) and 1,000 milligrams of a long-acting androgen called testosterone undecanoate (TU) for up to 26 weeks to suppress their sperm counts.
The hormones were effective in reducing the sperm count to 1 million/ml or less within 24 weeks in 274 of the participants. The contraceptive method was effective in nearly 96 per cent of continuing users. In comparison, the effect of the pill was 99.9 per cent.
Despite the adverse effects, including injection site pain, muscle pain, increased libido and acne, more than 75 per cent of participants reported being willing to use this method of contraception at the conclusion of the trial.
"Our findings confirmed the efficacy of this contraceptive method previously seen in small studies," Festin said.
Researchers are still working to perfect the combination of hormonal contraceptives to reduce the risk of mild to moderate side effects, including depression and other mood disorders.
The study was published in the Journal of Clinical Endocrinology & Metabolism.
--IANS
rt/sm/dg
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
